The Cost of Neurodevelopmental Disability: Scoping Review of Economic Evaluation Methods

References

• Thapar A, Cooper M, Rutter M. Neurodevelopmental disorders. Lancet Psychiatry. 2017;4:339–346. doi:10.1016/S2215-0366(16)30376-5
   PubMed Web of Science ®Google Scholar
• Gonzalez VJ, Kimbro RT, Cutitta KE, et al. Mental health disorders in children with congenital heart disease. Pediatrics. 2021;147(2). doi:10.1542/peds.2020-1693
   PubMed Web of Science ®Google Scholar
• Nattel SN, Adrianzen L, Kessler EC, et al. Congenital heart disease and neurodevelopment: clinical manifestations, genetics, mechanisms, and implications. Canad J Cardiol. 2017;33(12):1543–1555. doi:10.1016/j.cjca.2017.09.020
   PubMed Web of Science ®Google Scholar
• Graves N. Make economics your friend. J Hosp Infect. 2018;100(2):123–129. doi:10.1016/j.jhin.2018.07.008
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices—overview: a report of the ISPOR-SMDM modeling good research practices task force–1. Med Decis Making. 2012;32(5):667–677. doi:10.1177/0272989X12454577
   PubMed Web of Science ®Google Scholar
• Pinborough-Zimmerman J, Satterfield R, Miller J, Bilder D, Hossain S, McMahon W. Communication disorders: prevalence and comorbid intellectual disability, autism, and emotional/behavioral disorders. Am J Speech-Language Pathol. 2007;16:359. doi:10.1044/1058-0360(2007/039)
   PubMed Web of Science ®Google Scholar
• Thomas R, Sanders S, Doust J, Beller E, Glasziou P. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics. 2015;135(4):e994–e1001. doi:10.1542/peds.2014-3482
   PubMed Web of Science ®Google Scholar
• Maenner MJ, Blumberg SJ, Kogan MD, Christensen D, Yeargin-Allsopp M, Schieve LA. Prevalence of cerebral palsy and intellectual disability among children identified in two U.S. National Surveys, 2011–2013. Ann Epidemiol. 2016;26(3):222–226. doi:10.1016/j.annepidem.2016.01.001
   PubMed Web of Science ®Google Scholar
• Yang S, Xia J, Gao J, Wang L. Increasing prevalence of cerebral palsy among children and adolescents in China 1988–2020: a systematic review and meta-analysis. J Rehabil Med. 2021;53(5):jrm00195–jrm00195. doi:10.2340/16501977-2841
   PubMed Web of Science ®Google Scholar
• Sampaio F, Feldman I, Lavelle TA, Skokauskas N. The cost-effectiveness of treatments for attention deficit-hyperactivity disorder and autism spectrum disorder in children and adolescents: a systematic review. Eur Child Adolesc Psychiatry. 2021. doi:10.1007/s00787-021-01748-z
   Web of Science ®Google Scholar
• Hurley-Hanson AE, Giannantonio CM, Griffiths AJ. Autism in the Workplace: Creating Positive Employment and Career Outcomes for Generation A. Springer; 2020.
   Google Scholar
• Quintero J, Ramos-Quiroga JA, San Sebastián J, et al. Health care and societal costs of the management of children and adolescents with attention-deficit/hyperactivity disorder in Spain: a descriptive analysis. BMC Psychiatry. 2018;18(1):1–10. doi:10.1186/s12888-017-1581-y
   PubMed Web of Science ®Google Scholar
• Deloitte Access Economics. The social and economic costs of ADHD in Australia. Available from: https://www2.deloitte.com/au/en/pages/economics/articles/social-economic-costs-adhd-Australia.html. Accessed July 30, 2021.
   Google Scholar
• Le HH, Hodgkins P, Postma MJ, et al. Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case. Eur Child Adolesc Psychiatry. 2014;23(7):587–598. doi:10.1007/s00787-013-0477-8
   PubMed Web of Science ®Google Scholar
• Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222.
   PubMed Web of Science ®Google Scholar
• Institue for Health Metrics and Evaluation. Global burden of disease compare. Institue for Health Metrics and Evaluation; 2019. Available from: https://vizhub.healthdata.org/gbd-compare/. Accessed Jul 29, 2021.
   Google Scholar
• Leigh JP, Du J. Brief report: forecasting the economic burden of autism in 2015 and 2025 in the United States. J Autism Dev Disord. 2015;45(12):4135–4139. doi:10.1007/s10803-015-2521-7
   PubMed Web of Science ®Google Scholar
• Loe IM, Feldman HM. Academic and educational outcomes of children with ADHD. J Pediatr Psychol. 2007;32(6):643–654. doi:10.1093/jpepsy/jsl054
   PubMed Web of Science ®Google Scholar
• Wehman P, Schall C, McDonough J, et al. Project SEARCH for youth with autism spectrum disorders: increasing competitive employment on transition from high school. J Posit Behav Interv. 2013;15(3):144–155. doi:10.1177/1098300712459760
   Web of Science ®Google Scholar
• Murphy NA, Carbone PS. Promoting the participation of children with disabilities in sports, recreation, and physical activities. Pediatrics. 2008;121(5):1057–1061. doi:10.1542/peds.2008-0566
   PubMed Web of Science ®Google Scholar
• Leitch S, Sciberras E, Post B, et al. Experience of stress in parents of children with ADHD: a qualitative study. Int J Qual Stud Health Well-Being. 2019;14(1):1690091. doi:10.1080/17482631.2019.1690091
   PubMed Web of Science ®Google Scholar
• Stabile M, Allin S. The economic costs of childhood disability. Future Children. 2012;22(1):65–96. doi:10.1353/foc.2012.0008
   PubMed Web of Science ®Google Scholar
• Kalyva E, Kyriazi M, Vargiami E, Zafeiriou DI. A review of co-occurrence of autism spectrum disorder and Tourette syndrome. Res Autism Spectr Disord. 2016;24:39–51. doi:10.1016/j.rasd.2016.01.007
   Web of Science ®Google Scholar
• Gargaro BA, Rinehart NJ, Bradshaw JL, Tonge BJ, Sheppard DM. Autism and ADHD: how far have we come in the comorbidity debate? Neurosci Biobehav Rev. 2011;35(5):1081–1088. doi:10.1016/j.neubiorev.2010.11.002
   PubMed Web of Science ®Google Scholar
• Beecham J. Annual Research Review: child and adolescent mental health interventions: a review of progress in economic studies across different disorders. J Child Psychol Psychiatry. 2014;55(6):714–732. doi:10.1111/jcpp.12216
   PubMed Web of Science ®Google Scholar
• Kilian R, Losert C, Park AL, McDaid D, Knapp M. Cost-effectiveness analysis in child and adolescent mental health problems: an updated review of literature. Int J Mental Health Promot. 2010;12(4):45–57. doi:10.1080/14623730.2010.9721825
   Google Scholar
• Romeo R, Byford S, Knapp M. Annotation: economic evaluations of child and adolescent mental health interventions: a systematic review. J Child Psychol Psychiatry. 2005;46(9):919–930. doi:10.1111/j.1469-7610.2005.00407.x
   PubMed Web of Science ®Google Scholar
• Munn Z, Peters MD, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med Res Methodol. 2018;18(1):1–7. doi:10.1186/s12874-018-0611-x
   PubMed Web of Science ®Google Scholar
• Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32. doi:10.1080/1364557032000119616
   Google Scholar
• Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5(1):69. doi:10.1186/1748-5908-5-69
   PubMed Web of Science ®Google Scholar
• Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–473. doi:10.7326/M18-0850
   PubMed Web of Science ®Google Scholar
• Peters MD, Godfrey CM, McInerney P, et al. Scoping reviews. In: Aromataris E, Z M, editors. JBI Manual for Evidence Synthesis; 2020:chap 10. doi:10.46658/JBIMES-20-12
   Google Scholar
• Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. doi:10.1186/s13643-016-0384-4
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Cost Eff Resour Alloc. 2013;11(1):6. doi:10.1016/j.jval.2013.02.010
   PubMed Web of Science ®Google Scholar
• Maia CR, Stella SF, Wagner F, et al. Cost-utility analysis of methylphenidate treatment for children and adolescents with ADHD in Brazil. Revista Brasileira de Psiquiatria. 2016;38(1):30–38. doi:10.1590/1516-4446-2014-1516
   PubMed Web of Science ®Google Scholar
• Freriks RD, Mierau JO, van der Schans J, et al. Cost-effectiveness of treatments in children with attention-deficit/hyperactivity disorder: a continuous-time Markov modeling approach. MDM Policy Pract. 2019;4(2):2381468319867629. doi:10.1177/2381468319867629
   Google Scholar
• Schawo S, van der Kolk A, Bouwmans C, et al. Probabilistic Markov model estimating cost effectiveness of methylphenidate osmotic-release oral system versus immediate-release methylphenidate in children and adolescents: which information is needed? Pharmacoeconomics. 2015;33(5):489–509. doi:10.1007/s40273-015-0259-x
   PubMed Web of Science ®Google Scholar
• Faber A, van Agthoven M, Kalverdijk LJ, et al. Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. CNS Drugs. 2008;22(2):157–170. doi:10.2165/00023210-200822020-00006
   PubMed Web of Science ®Google Scholar
• Denchev P, Kaltman JR, Schoenbaum M, Vitiello B. Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder. Circulation. 2010;121(11):1329–1337. doi:10.1161/CIRCULATIONAHA.109.901256
   PubMed Web of Science ®Google Scholar
• van der Schans J, Kotsopoulos N, Hoekstra PJ, Hak E, Postma MJ. Cost-effectiveness of extended-release methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder sub-optimally treated with immediate release methylphenidate. PLoS One. 2015;10(5):e0127237. doi:10.1371/journal.pone.0127237
   PubMed Web of Science ®Google Scholar
• Penner M, Rayar M, Bashir N, Roberts S, Hancock-Howard R. Coyte. cost-effectiveness analysis comparing pre-diagnosis autism spectrum disorder (ASD)-targeted intervention with ontario’s autism intervention program. J Autism Dev Disord. 2015;45(9):2833–28472815. doi:10.1007/s10803-015-2447-0
   PubMed Web of Science ®Google Scholar
• Piccininni C, Bisnaire L. Cost-effectiveness of wait time reduction for intensive behavioral intervention services in Ontario, Canada. JAMA Pediatr. 2017;171(1):23–30. doi:10.1001/jamapediatrics.2016.2695
   PubMed Web of Science ®Google Scholar
• Mark R, David M, Mark S, et al. Interventions based on early intensive applied behaviour analysis for autistic children: a systematic review and cost-effectiveness analysis. NIHR Health Technology Assessment programme; 2020.
   Google Scholar
• Vallejo-Torres L, Rivero-Santana A, Martin-Saborido C, et al. Cost-effectiveness analysis of a surveillance program to prevent Hip dislocation in children with cerebral palsy. Gaceta sanitaria. 2019;2019:56.
   Google Scholar
• Kazarian GS, Van Heest AE, Goldfarb CA, Wall LB. Cost comparison of botulinum toxin injections versus surgical treatment in pediatric patients with cerebral palsy: a Markov model. J Hand Surg Am. 2021;46(5):359–367. doi:10.1016/j.jhsa.2021.01.018
   PubMed Web of Science ®Google Scholar
• Hakkaart-van Roijen L, Goettsch WG, Ekkebus M, Gerretsen P, Stolk E. The cost-effectiveness of an intensive treatment protocol for severe dyslexia in children. Dyslexia. 2011;17(3):256–267. doi:10.1002/dys.436
   PubMed Web of Science ®Google Scholar
• McPhail SM. Multimorbidity in chronic disease: impact on health care resources and costs. Risk Manag Healthc Policy. 2016;9:143–156. doi:10.2147/rmhp.S97248
   PubMed Web of Science ®Google Scholar
• Tilford JM, Payakachat N, Kovacs E, et al. Preference-based health-related quality-of-life outcomes in children with autism spectrum disorders. PharmacoEconomics. 2012;30(8):661–679. doi:10.2165/11597200-000000000-00000
   PubMed Web of Science ®Google Scholar
• Lamsal R, Zwicker JD. Economic evaluation of interventions for children with neurodevelopmental disorders: opportunities and challenges. Appl Health Econ Health Policy. 2017;15(6):763–772. doi:10.1007/s40258-017-0343-9
   PubMed Web of Science ®Google Scholar
• Chen G, Ratcliffe J. A review of the development and application of generic multi-attribute utility instruments for paediatric populations. PharmacoEconomics. 2015;33(10):1013–1028. doi:10.1007/s40273-015-0286-7
   PubMed Web of Science ®Google Scholar
• Dieng M, Kasparian NA, Cust AE, et al. Sensitivity of preference-based quality-of-life measures for economic evaluations in early-stage Melanoma. JAMA dermatol. 2018;154(1):52–59. doi:10.1001/jamadermatol.2017.4701
   PubMed Web of Science ®Google Scholar
• Lin P-J, D’Cruz B, Leech AA, et al. Family and caregiver spillover effects in cost-utility analyses of Alzheimer’s disease interventions. PharmacoEconomics. 2019;37(4):597–608. doi:10.1007/s40273-019-00788-3
   PubMed Web of Science ®Google Scholar
• Lavelle TA, D’Cruz BN, Mohit B, et al. Family spillover effects in pediatric cost-utility analyses. Appl Health Econ Health Policy. 2019;17(2):163–174. doi:10.1007/s40258-018-0436-0
   PubMed Web of Science ®Google Scholar
• Ungar WJ. Challenges in health state valuation in paediatric economic evaluation. PharmacoEconomics. 2011;29(8):641–652. doi:10.2165/11591570-000000000-00000
   PubMed Web of Science ®Google Scholar
• Petrou S, Gray A. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ. 2011;342:32.
   Google Scholar
• Zimmerman MS, Smith AGC, Sable CA, et al. Global, regional, and national burden of congenital heart disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Child Adolesc Health. 2020;4(3):185–200. doi:10.1016/S2352-4642(19)30402-X
   PubMedGoogle Scholar